LIST OF PARTICIPANTS

Members

Bruce C. Baguley, University of Auckland, New Zealand
Frederick A. Beland, National Center for Toxicological Research, USA
Joseph M. Betz, Office of Dietary Supplements, USA (Subgroup Chair, Exposure data)
Robert J. Biggar, Queensland University of Technology, Australia
Esperanza J. Carcache de Blanco, Ohio State University, USA
Michael L. Cunningham, National Institute of Environmental Health Sciences, USA (retired)
June K. Dunnick, National Institute of Environmental Health Sciences, USA
Lei Guo, National Center for Toxicological Research, USA
Charles W. Jameson, CWJ Consulting, LLC, USA (Subgroup Chair, Cancer in experimental animals)
Margaret Karagas, Dartmouth Medical School, USA (Subgroup Chair, Cancer in humans)
Trudy L. Knight, University of Birmingham, United Kingdom
Dirk W. Lachenmeier, Ministry of Rural Region and Consumer Protection in Baden-Württemberg, Germany
Ruth M. Lunn, National Institute of Environmental Health Sciences, USA
M. Matilde Marques, Technical University of Lisbon, Portugal (Subgroup Chair, Mechanisms)
David L. McCormick, IIT Research Institute, USA
Saranjit Singh, National Institute of Pharmaceutical Education and Research, India (unable to attend)
Sonal Singh, Johns Hopkins University, USA
Bernard W. Stewart, South Eastern Sydney Public Health Unit, Australia (Overall Chair)
Chin-Hsiao Tseng, Taiwan University, Taiwan, China
Hiroyuki Tsuda, Nagoya City University, Japan
Kristine L. Witt, National Institute of Environmental Health Sciences, USA (unable to attend)
Shufeng Zhou, College of Pharmacy, USA

Invited Specialists

Randall S. Stafford, Stanford Prevention Research Center, USA

1 Chin-Hsiao Tseng received non-significant honoraria for serving on advisory boards and presentations from pharmaceutical companies, including Bristol-Myers-Squibb Company, Eli Lilly and Company, and Takeda Pharmaceutical Company Limited.
2 Randall S. Stafford provided expert testimony (ceased in 2011) for Mylan Pharmaceuticals, Morgantown, WV, manufacturer of generic drugs, including hydrochlorothiazide containing drugs.
Representatives of national and international health agencies

None

Observers

David Alexander, for Williams Kherkher Hart Boundas, LLP, USA\(^3\)
Andrea Bertocco, for Herbalife Europe Limited, United Kingdom\(^4\)
Paul Dolin, for Takeda Global Research & Development Centre (Europe) Ltd, United Kingdom\(^5\)
Olaf Kelber, for the World Self-Medication Industry (WSMI), France\(^6\)
Egon Koch, for the World Self-Medication Industry (WSMI), France\(^7\)

IARC secretariat

Melina Arnold, Section of Cancer Information
Robert Baan, Visiting Scientist, Section of IARC Monographs
Helen Bailey, Section of Environment and Radiation
Lamia Benbrahim-Tallaa, Section of IARC Monographs
Véronique Bouvard, Section of IARC Monographs
Fatiha El Ghissassi, Section of IARC Monographs
Akram Ghantous, Section of Mechanisms of Carcinogenesis
Yann Grosse, Section of IARC Monographs (Responsible Officer)
Neela Guha, Section of IARC Monographs
Béatrice Lauby-Secretan, Section of IARC Monographs
Ho-Sun Lee, Section of Mechanisms of Carcinogenesis
Dana Loomis, Section of IARC Monographs
Heidi Mattock, Section of IARC Monographs (Editor)
Douglas Puricelli Perin, Section of IARC Monographs
Monica Sierra, Section of Cancer Information
Kurt Straif, Section of IARC Monographs (Section Head)
Jiri Zavadil, Section of Mechanisms of Carcinogenesis

---

\(^3\) David Alexander represents clients who claim they have been injured by the drug pioglitazone. He is employed and sponsored by Williams Kherkher Hart Boundas, LLP, Houston Texas, USA.

\(^4\) Andrea Bertocco is employed by Herbalife, where he served as regulatory Manager for Herbalife products containing Aloe Vera, Goldenseal and Ginkgo biloba. He is sponsored by Herbalife Europe Limited, United Kingdom.

\(^5\) Paul Dolin is employed and sponsored by Takeda Pharmaceutical Company Limited, Europe, manufacturing pioglitazone-containing and other pharmaceutical drugs. He holds stock of pharmaceutical companies marketing drugs that are reviewed at this meeting.

\(^6\) Olaf Kelber is employed by Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany, manufacturing herbal medicines. He is sponsored by the World-Self-Medication Industry (WSMI), France.

\(^7\) Egon Koch is employed by Dr. Wilmar Schwabe GmbH & Co KG, Karlsruhe, Germany. He provides expert testimony with respect to the commercialization of Ginkgo biloba extracts. He is sponsored by the World-Self-Medication Industry (WSMI), France.
NOTE REGARDING CONFLICTS OF INTERESTS: Each participant submitted WHO’s Declaration of Interests, which covers employment and consulting activities, individual and institutional research support, and other financial interests. Participants identified as Invited Specialists did not serve as meeting chair or subgroup chair, draft text that pertains to the description or interpretation of cancer data, or participate in the evaluations. The Declarations were updated and reviewed again at the opening of the meeting.

NOTE REGARDING OBSERVERS: Each Observer agreed to respect the Guidelines for Observers at IARC Monographs meetings. Observers did not serve as meeting chair or subgroup chair, draft any part of a Monograph, or participate in the evaluations. They also agreed not to contact participants before the meeting, not to lobby them at any time, not to send them written materials, and not to offer them meals or other favours. IARC asked and reminded Working Group Members to report any contact or attempt to influence that they may have encountered, either before or during the meeting.

Posted on 4 April 2013, updated on 5 June 2013